Conflict of interest. JSP and JRB are co-inventors on a patent entitled ‘Selective modulation of tumour necrosis factor receptors in therapy’.
Tumour necrosis factor and cancer
Article first published online: 7 JUN 2013
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 230, Issue 3, pages 241–248, July 2013
How to Cite
Waters, J. P., Pober, J. S. and Bradley, J. R. (2013), Tumour necrosis factor and cancer. J. Pathol., 230: 241–248. doi: 10.1002/path.4188
- Issue published online: 7 JUN 2013
- Article first published online: 7 JUN 2013
- Accepted manuscript online: 4 MAR 2013 01:13PM EST
- Manuscript Accepted: 23 FEB 2013
- Manuscript Revised: 15 FEB 2013
- Manuscript Received: 3 FEB 2013
- tumour necrosis factor;
- signal transduction;
- cell death;
- cell survival;
Tumour necrosis factor (TNF) was originally described as a circulating factor that can induce haemorrhagic necrosis of tumours. It is now clear that TNF has many different functions in cancer biology. In addition to causing the death of cancer cells, TNF can activate cancer cell survival and proliferation pathways, trigger inflammatory cell infiltration of tumours and promote angiogenesis and tumour cell migration and invasion. These effects can be explained by the diverse cellular responses TNF can initiate through distinct signal transduction pathways, opening the way for more selective targeting of TNF signalling in cancer therapy. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.